Total Payments
$195,204
2024 Payments
$404.47
Companies
10
Transactions
245
Medicare Patients
593
Medicare Billing
$68,734
Payment Breakdown by Category
Other$152,812 (78.3%)
Consulting$31,280 (16.0%)
Food & Beverage$6,270 (3.2%)
Travel$4,842 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,812 | 71 | 78.3% |
| Consulting Fee | $31,280 | 17 | 16.0% |
| Food and Beverage | $6,270 | 128 | 3.2% |
| Travel and Lodging | $4,842 | 29 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $101,093 | 120 | $0 (2024) |
| EMD Serono, Inc. | $63,649 | 73 | $0 (2024) |
| Acorda Therapeutics, Inc | $22,257 | 19 | $0 (2018) |
| Celgene Corporation | $7,457 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $284.13 | 8 | $0 (2024) |
| Genentech USA, Inc. | $241.61 | 8 | $0 (2024) |
| Genentech, Inc. | $149.14 | 2 | $0 (2018) |
| UCB, Inc. | $27.64 | 1 | $0 (2024) |
| ABBVIE INC. | $27.42 | 1 | $0 (2023) |
| Depomed, Inc. | $18.21 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $404.47 | 18 | Celgene Corporation ($131.57) |
| 2023 | $10,013 | 21 | Biogen, Inc. ($9,841) |
| 2022 | $21,468 | 28 | Biogen, Inc. ($14,608) |
| 2021 | $22,911 | 21 | Biogen, Inc. ($13,595) |
| 2020 | $21,185 | 29 | EMD Serono, Inc. ($17,896) |
| 2019 | $34,974 | 38 | Biogen, Inc. ($21,125) |
| 2018 | $47,750 | 56 | Biogen, Inc. ($28,197) |
| 2017 | $36,498 | 34 | Acorda Therapeutics, Inc ($16,687) |
All Payment Transactions
245 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $26.10 | General |
| Category: Neurology | ||||||
| 10/26/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.45 | General |
| 10/03/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Neurology | ||||||
| 10/02/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $36.89 | General |
| Category: Neuroscience | ||||||
| 09/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.32 | General |
| Category: Neuroscience | ||||||
| 09/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Neurology | ||||||
| 07/25/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Neurology | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: Neurology | ||||||
| 05/08/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $37.80 | General |
| Category: Neuroscience | ||||||
| 05/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Neurology | ||||||
| 04/18/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Neurology | ||||||
| 02/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $28.43 | General |
| Category: Neuroscience | ||||||
| 02/15/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Neurology | ||||||
| 02/14/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Neurology | ||||||
| 01/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $8.13 | General |
| Category: Neuroscience | ||||||
| 01/18/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Immunology | ||||||
| 01/11/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Neurology | ||||||
| 11/16/2023 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,448.00 | General |
| 11/16/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $91.00 | General |
| 11/16/2023 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $7.47 | General |
| Category: Neurology | ||||||
| 11/09/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Neurology | ||||||
| 09/19/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Neurology | ||||||
| 08/25/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $35.12 | General |
| Category: Neurology | ||||||
| 08/22/2023 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,040.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 186 | 216 | $87,373 | $24,213 |
| 2022 | 5 | 163 | 178 | $73,477 | $20,679 |
| 2021 | 3 | 130 | 164 | $38,996 | $13,475 |
| 2020 | 2 | 114 | 148 | $41,629 | $10,367 |
Total Patients
593
Total Services
706
Medicare Billing
$68,734
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $37,952 | $10,898 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 65 | $22,490 | $6,063 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 42 | $10,290 | $2,788 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $10,327 | $2,709 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $5,346 | $1,468 | 27.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 11 | 11 | $968.00 | $287.10 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 54 | 54 | $31,806 | $9,330 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $12,934 | $3,676 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 32 | $11,072 | $3,328 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 23 | $11,086 | $3,319 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 23 | 23 | $5,083 | $573.62 | 11.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 11 | 17 | $1,496 | $452.54 | 30.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 81 | 103 | $22,763 | $7,966 | 35.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 33 | 42 | $13,440 | $4,626 | 34.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 16 | 19 | $2,793 | $882.93 | 31.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 60 | 77 | $25,378 | $6,423 | 25.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 54 | 71 | $16,251 | $3,944 | 24.3% |
About Dr. Michael Ko, MD
Dr. Michael Ko, MD is a Neurology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922088111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ko, MD has received a total of $195,204 in payments from pharmaceutical and medical device companies, with $404.47 received in 2024. These payments were reported across 245 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($152,812).
As a Medicare-enrolled provider, Ko has provided services to 593 Medicare beneficiaries, totaling 706 services with total Medicare billing of $68,734. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Chicago, IL
- Active Since 01/23/2006
- Last Updated 01/24/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1922088111
Products in Payments
- TYSABRI (Biological) $39,880
- Mavenclad (Drug) $33,260
- AMPYRA (Drug) $22,257
- TECFIDERA (Drug) $20,027
- Rebif (Biological) $15,831
- Mavenclad (Biological) $13,706
- Ozanimod (Drug) $6,727
- VUMERITY (Drug) $6,194
- Tysabri (Biological) $5,043
- OCREVUS (Biological) $316.58
- ZEPOSIA (Drug) $162.42
- KESIMPTA (Drug) $159.13
- GILENYA (Drug) $125.00
- ZINBRYTA (Biological) $111.58
- Enspryng (Biological) $48.79
- MAVENCLAD (Drug) $35.12
- Fintepla (Drug) $27.64
- BOTOX (Biological) $27.42
- Ocrevus (Biological) $25.38
- Nucynta (Drug) $18.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Chicago
Mr. Augusto Miravalle, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Adil Javed
Neurology — Payments: $1.0M
Neurology $1.0M
Douglas Nordli, Md, MD
Neurology — Payments: $654,190
Neurology $654,190
Dr. Dusan Stefoski, Md, MD
Neurology — Payments: $610,165
Neurology $610,165
Dr. Danny Bega, M.d, M.D
Neurology — Payments: $432,383
Neurology $432,383
Tatyana Simuni, Md, MD
Neurology — Payments: $385,696
Neurology $385,696